# IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children

> **NIH ALLCDC U01** · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · 2024 · $1,234,285

## Abstract

Component A: Project Summary
The Kansas City-New Vaccine Surveillance Network (KC-NVSN) program has been performing
population-based, laboratory-confirmed, active surveillance of acute gastroenteritis (AGE) illness
and acute respiratory illness (ARI) in children seeking care at Children’s Mercy (CM), in Kansas
City (KC), MO since 2009 and 2015, respectively.
In the current proposal, the KC-NVSN program seeks to continue the existing pediatric AGE and
expand the pediatric ARI surveillance to the six county KC metropolitan area for children seen in
CM’s inpatient and emergency department (ED) settings. Age- and time-matched healthy control
children seeking well-child care in the outpatient setting will also be enrolled. We will enroll eligible
children (as defined in the proposal) visiting or admitted to our hospital system using permission
and assent forms approved by CM’s institutional review board (IRB). After enrollment, we will
interview parents, collect EMR chart data, and retrieve hard copies of receipt of influenza and
rotavirus (RV) vaccine, and any future vaccines (SARS-CoV-2, RSV, NoV). Stool specimens will
be tested for RV, norovirus (NoV), and other GI pathogens, and respiratory specimens for 23
respiratory pathogens, e.g., influenza (types and specific subtypes) and other non-influenza
viruses (RSV, EV-D68, and SARS-CoV-2, etc). We will use prospective surveillance for acute
flaccid myelitis (AFM) characterizing the clinical disease spectrum and burden rates. KC-NVSN
data will provide population-based estimates to address the following specific aims:
 1. To assess the burden of AGE and ARI pathogens among enrolled children.
2. To assess vaccine effectiveness (VE) against medically attended illness due to RV,
 influenza, and upcoming vaccines via laboratory-confirmed testing among enrolled children.
 3. To assess AFM clinical spectra and burden and associations with ARI and AGE illnesses.
The KC-NVSN program data will be combined with other geographically diverse sites’ data to
estimate the national incidence, burden, and etiology of community-acquired AGE and ARI and
VE for rotavirus and seasonal influenza vaccinations. This network will also address several
important scientific questions related to the natural history of pediatric infectious diseases,
transmission dynamics, impact of vaccine on targeted and vulnerable populations, and factors
influencing VE. The surveillance data generated from this network will provide timely and highly
useful data to inform public health measures and pediatric vaccine-related policies aimed at
controlling AGE and ARI in US children.

## Key facts

- **NIH application ID:** 11046484
- **Project number:** 5U01IP001154-04
- **Recipient organization:** CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
- **Principal Investigator:** Jennifer E Schuster
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2024
- **Award amount:** $1,234,285
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11046484

## Citation

> US National Institutes of Health, RePORTER application 11046484, IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children (5U01IP001154-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11046484. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*